PET/CT and renal pathology: A blind spot for radiologists? Part 1, primary pathology

Katherine Zukotynski, Aaron Lewis, Kevin O'Regan, Heather Jacene, Christopher Sakellis, Katherine Krajewski, David Israel

Research output: Contribution to journalReview article

Abstract

OBJECTIVE. PET/CT with 18F-FDG shows metabolically active disease and is widely used for the diagnosis and follow-up of patients with cancer. Nonmetabolically active renal pathology may be missed without close attention to the CT portion of the study, whereas metabolically active pathology may be missed on PET because of physiologic tracer excretion in the kidneys. This article illustrates primary lesions of the kidney on FDG PET/CT with emphasis on key anatomic features and the appearance of tracer uptake. CONCLUSION. Close attention to both the FDG PET and CT portions of the study is essential to interpret renal pathology correctly on FDG PET/CT examinations.

Original languageEnglish (US)
Pages (from-to)W163-W167
JournalAmerican Journal of Roentgenology
Volume199
Issue number2
DOIs
StatePublished - Aug 1 2012

Keywords

  • FDG PET/CT
  • Oncology
  • Renal pathology

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'PET/CT and renal pathology: A blind spot for radiologists? Part 1, primary pathology'. Together they form a unique fingerprint.

  • Cite this

    Zukotynski, K., Lewis, A., O'Regan, K., Jacene, H., Sakellis, C., Krajewski, K., & Israel, D. (2012). PET/CT and renal pathology: A blind spot for radiologists? Part 1, primary pathology. American Journal of Roentgenology, 199(2), W163-W167. https://doi.org/10.2214/AJR.11.7790